Breast | Maryland Oncology Hematology Breast – Maryland Oncology Hematology

Trial ID ESR 22-21698 (EIMPRIS)

NCT05438498 ID
Phase II/III

Trial ID 21455

NCT05296798 ID
USOR ID: 21455 Phase III
Phase III, 2 Arm, Randomized, Open Label, Multicenter, Registrational Study Evaluating The Efficacy And Safety Of Giredestrant In Combination With Phesgo Versus Phesgo (+/- Endocrine Therapy) After Induction Chemotherapy (Phesgo+Taxane) In Patients With Previously Untreated Her2-Positive, Estrogen Receptor Positive Locally Advanced Or Metastatic Breast Cancer

Trial ID 17079

NCT03053193 ID
USOR ID: 17079
FLEX: MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry

Trial ID

NCT04916808 ID

Trial ID 21448

NCT05113966 ID
USOR ID: 21448 Phase II
A Phase 2, Single-Arm, Open-Label Study of Trilaciclib Administered Prior to Sacituzumab Govitecan-hziy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments, at Least One in the Metastatic Setting (G1T28-213)

Trial ID 19226

NCT04546009 ID
USOR ID: 19226 Phase III

Trial ID 20363

NCT04711252 ID
USOR ID: 20363 Phase III
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

Trial ID 20396

NCT04784715 ID
USOR ID: 20396 Phase III
DESTINY09: A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in First-line HER2-positive Breast Cancer

Trial ID 20326

NCT04906395 ID
USOR ID: 20326 Phase III
OVELIA: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Trial ID 21462

NCT05232916 ID
USOR ID: 21462 Phase III
FLAMINGO-01: A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy

Trial ID 22080

USOR ID: 22080 Phase III
CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant(AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in patients with HR+/HER2- early breast cancer and a intermediate or high risk of recurrence who have completed definitive locoregional therapy and at least 2 years of adjuvant endocrine therapy without disease recurrence

Trial ID 22101

NCT05514054 ID
USOR ID: 22101 Phase III
EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence

Trial ID 21380

NCT05169567 ID
USOR ID: 21380 Phase III
postMONARCH: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+, HER2-, Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy

Trial ID 20289

NCT04254107 ID
USOR ID: 20289 Phase I
A Phase 1 Study of SEA-TGT (SGN-TGT) in Subjects with Advanced Malignancies

Trial ID 21494

NCT05304962 ID
USOR ID: 21494 Phase I
First-in-Human, Escalating Oral Dose Study of RGT-419B Given Alone and with Endocrine Therapy in Subjects with Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Advanced/Metastatic Breast Cancer

Trial ID 14059

NCT03379428 ID
USOR ID: 14059 Phase I/II
Phase I/II trial of Ibrutinib plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

Trial ID 20266

NCT04485013 ID
USOR ID: 20266 Phase Ib
A Phase 1a/1b Dose Escalation/Expansion Study of TTX-080, an HLA-G Antagonist, as Monotherapy and in Combination with Pembrolizumab or Cetuximab in Patients with Advanced Solid Refractory/Resistant Malignancies

Trial ID

NCT04589845 ID
Phase II

Trial ID 21501

NCT05065411 ID
USOR ID: 21501 Phase II
ARTEST: A Phase 2 Study to Evaluate the Efficacy and Safety of Enobosarm in Combination with Abemaciclib (Enobosarm Combination Group) compared to Estrogen Blocking Agent (Control Treated Group) for the Second Line Treatment of ER+HER2- Metastatic Breast Cancer in Patients Who Have Shown Previous Disease Progression on an Estrogen Blocking Agent plus Palbociclib

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology